Nevirapine‐associated toxicity in HIV‐infected Thai men and women, including pregnant women

The aim of the study was to determine the incidence of, and risk factors for, nevirapine (NVP)‐associated hepatotoxicity and rash in HIV‐infected Thai men and women, including pregnant women, receiving NVP‐containing highly active antiretroviral therapy (HAART).

[1]  L. Waters,et al.  8th International Congress on Drug Therapy in HIV Infection , 2007 .

[2]  S. Koletar,et al.  Third-Trimester Maternal Toxicity With Nevirapine Use in Pregnancy , 2005, Obstetrics and gynecology.

[3]  C. Zorrilla,et al.  Protease Inhibitor Use in 233 Pregnancies , 2005, Journal of acquired immune deficiency syndromes.

[4]  J. Dieleman,et al.  Nelfinavir and nevirapine side effects during pregnancy , 2005, AIDS.

[5]  J. Ananworanich,et al.  Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs , 2005, AIDS.

[6]  C. Moore,et al.  Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts , 2005, AIDS.

[7]  E. Naik,et al.  Effectiveness of Generic Fixed-Dose Combinations of Highly Active Antiretroviral Therapy for Treatment of HIV Infection in India , 2004, Journal of acquired immune deficiency syndromes.

[8]  Lee-Jen Wei,et al.  Maternal Toxicity With Continuous Nevirapine in Pregnancy: Results From PACTG 1022 , 2004, Journal of acquired immune deficiency syndromes.

[9]  B. Gazzard,et al.  Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.

[10]  R. Johann-Liang,et al.  Hepatotoxicity associated with nevirapine use. , 2004, Journal of acquired immune deficiency syndromes.

[11]  D. Dieterich,et al.  Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  S. Becker.  Liver toxicity in epidemiological cohorts. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Beijnen,et al.  Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment , 2003, AIDS.

[14]  D. Mayers,et al.  A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients* , 2003, Journal of acquired immune deficiency syndromes.

[15]  J. Beijnen,et al.  Incidence and risk factors for nevirapine-associated rash , 2003, European Journal of Clinical Pharmacology.

[16]  Julio S. G. Montaner,et al.  Randomized, Controlled Study of the Effects of a Short Course of Prednisone on the Incidence of Rash Associated With Nevirapine in Patients Infected With HIV‐1 , 2003, Journal of acquired immune deficiency syndromes.

[17]  V. Soriano,et al.  Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine , 2003, HIV clinical trials.

[18]  S. Lawson-Ayayi,et al.  A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  P. Easterbrook,et al.  Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. , 2002, AIDS.

[20]  M. Mitka.  MTCT-Plus program has two goals: end maternal HIV transmission + treat mothers. , 2002, JAMA.

[21]  V. Soriano,et al.  Liver toxicity caused by nevirapine. , 2002, AIDS.

[22]  James B. Hill,et al.  Hepatotoxicity With Antiretroviral Treatment of Pregnant Women , 2001, Obstetrics and gynecology.

[23]  G. Ippolito,et al.  Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. , 2001, AIDS.

[24]  Andrew Phillips,et al.  Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy , 2001, AIDS.

[25]  C. Sabin,et al.  Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine. , 2001, Journal of acquired immune deficiency syndromes.

[26]  P. Easterbrook,et al.  Experience of nevirapine use in a London cohort of HIV‐infected pregnant women , 2001, HIV medicine.

[27]  D. Cooper,et al.  Adverse effects of antiretroviral therapy , 2000, The Lancet.

[28]  V. Soriano,et al.  Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids , 2000, AIDS.

[29]  V. Soriano,et al.  Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash? , 2000, AIDS.

[30]  C. Kemper,et al.  Frequency of Cutaneous Reactions on Rechallenge with Nevirapine and Delavirdine , 2000, The Annals of pharmacotherapy.

[31]  M. Deltenre,et al.  Fatal liver failure associated with Nevirapine in a pregnant HIV patient: The first reported case , 2000 .

[32]  R. Pollard,et al.  Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. , 1998, Clinical therapeutics.

[33]  K. Wong,et al.  High incidence of nevirapine-associated rash in HIV-infected Chinese. , 1998, AIDS.